In screening campaigns for tumor neoepitope-reactive T cells with peptide-loaded MHC multimers we encountered the need to cover a variety of rare HLA-A, -B, and -C allotypes that are presently not commercially available as recombinant MHC-I molecules. Here, HLA-C is linked to neoplasm.